China-based HitGen Inc. (SHA: 688222) has announced a partnership with UK-headquartered C4X Discovery Holdings plc (AIM: C4XD) to identify novel, small-molecule hits against an inflammatory target for further development by C4XD. The collaboration leverages HitGen’s expertise in DNA-encoded library (DEL) screening technology to identify potential drug candidates. No financial details were disclosed.
Collaboration Details
C4XD and HitGen have developed an initial approach where HitGen will apply its DEL screening technology platform to identify hits against a commercially valuable target for inflammatory diseases. If successful, C4XD will then use its molecule design Conformetrix technology to translate these hits into suitable starting points for a small-molecule drug program. This program can then be progressed through C4XD’s rigorous drug discovery process. C4XD also has the option to extend the collaboration with HitGen during the drug discovery phase to leverage HitGen’s growing R&D capabilities.
C4XD’s Drug Discovery Approach
C4XD is known for its highly differentiated approach to drug discovery through enhanced DNA-based target identification and candidate molecule design capabilities. The company generates small molecule drug candidates across multiple disease areas, including inflammation, oncology, neurodegeneration, and addictive disorders. C4XD currently has two commercial collaboration programs, with one candidate compound at the clinical stage. In April last year, C4XD licensed its IL-17A inhibitor to French major Sanofi in a deal worth EUR 414 million (USD 405 million).
Future Outlook
This partnership between HitGen and C4X Discovery highlights the growing collaboration between Chinese and European biotech companies to develop innovative treatments for inflammatory diseases. By combining HitGen’s DEL screening technology with C4XD’s Conformetrix platform, the collaboration aims to accelerate the discovery and development of new small-molecule therapies.-Fineline Info & Tech
